Kesselheim AS - Search Results

1

Global cooperation and early access-clinical outcomes matter.

Tibau A, Kesselheim AS. Tibau A, et al. Among authors: kesselheim as. Lancet Oncol. 2024 Jun;25(6):687-688. doi: 10.1016/S1470-2045(24)00210-9. Epub 2024 May 13. Lancet Oncol. 2024. PMID: 38754452 No abstract available.

2

Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis.

Vokinger KN, Hwang TJ, Grischott T, Reichert S, Tibau A, Rosemann T, Kesselheim AS. Vokinger KN, et al. Among authors: kesselheim as. Lancet Oncol. 2020 May;21(5):664-670. doi: 10.1016/S1470-2045(20)30139-X. Lancet Oncol. 2020. PMID: 32359489

3

Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration.

Molto C, Hwang TJ, Borrell M, Andres M, Gich I, Barnadas A, Amir E, Kesselheim AS, Tibau A. Molto C, et al. Among authors: kesselheim as. Cancer. 2020 Oct 1;126(19):4390-4399. doi: 10.1002/cncr.33095. Epub 2020 Jul 22. Cancer. 2020. PMID: 32697362 Free article.

4

Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe.

Vokinger KN, Hwang TJ, Daniore P, Lee CC, Tibau A, Grischott T, Rosemann TJ, Kesselheim AS. Vokinger KN, et al. Among authors: kesselheim as. JAMA Oncol. 2021 Sep 1;7(9):e212026. doi: 10.1001/jamaoncol.2021.2026. Epub 2021 Sep 16. JAMA Oncol. 2021. PMID: 34196656 Free PMC article.

5

Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis.

Vokinger KN, Hwang TJ, Carl DL, Laube Y, Ludwig WD, Naci H, Kesselheim AS. Vokinger KN, et al. Among authors: kesselheim as. Lancet Oncol. 2022 Apr;23(4):514-520. doi: 10.1016/S1470-2045(22)00073-0. Epub 2022 Mar 7. Lancet Oncol. 2022. PMID: 35271804

6

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia.

Hwang TJ, Kesselheim AS, Tibau A, Lee CC, Vokinger KN. Hwang TJ, et al. Among authors: kesselheim as. JCO Oncol Pract. 2022 Sep;18(9):e1522-e1532. doi: 10.1200/OP.21.00909. Epub 2022 Jun 22. JCO Oncol Pract. 2022. PMID: 35731996 Free PMC article.

7

Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies.

Tibau A, Hwang TJ, Molto C, Avorn J, Kesselheim AS. Tibau A, et al. Among authors: kesselheim as. JAMA Oncol. 2024 May 1;10(5):634-641. doi: 10.1001/jamaoncol.2024.0194. JAMA Oncol. 2024. PMID: 38573645

8

Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study.

Tibau A, Hwang TJ, Avorn J, Kesselheim AS. Tibau A, et al. Among authors: kesselheim as. BMJ. 2024 Aug 20;386:e079126. doi: 10.1136/bmj-2023-079126. BMJ. 2024. PMID: 39164034 Free PMC article.

9

Insulin access and affordability in the USA: anticipating the first interchangeable insulin product.

Luo J, Kesselheim AS, Sarpatwari A. Luo J, et al. Among authors: kesselheim as. Lancet Diabetes Endocrinol. 2020 May;8(5):360-362. doi: 10.1016/S2213-8587(20)30105-4. Epub 2020 Mar 20. Lancet Diabetes Endocrinol. 2020. PMID: 32203681 Free PMC article. No abstract available.

10

Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer: A Systematic Review and Meta-analysis.

Bloomfield D, D'Andrea E, Nagar S, Kesselheim A. Bloomfield D, et al. JAMA Oncol. 2022 Apr 1;8(4):537-545. doi: 10.1001/jamaoncol.2021.7230. JAMA Oncol. 2022. PMID: 35113135 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

755 results

Search Page

Filters